文献速递造血干细胞移植与细胞治疗

结合临床症状与生物标志物的新型MAGIC复合评分最能预测急性GVHD的治疗结局

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.
PubMed 文献 · Blood · 2024-01-01

研究基于MAGIC联盟1863例接受治疗的急性GVHD患者,随机分为训练集和验证集,利用分类回归树算法建立含低危层的Manhattan风险分组,并将血清GVHD生物标志物评分与Manhattan风险整合,形成3种MAGIC复合评分。复合评分对6个月非复发死亡的预测优于单纯临床症状系统,且评分升高与第28天治疗反应率降低相关。

要点

  • MAGIC复合评分对6个月非复发死亡的预测优于Manhattan风险(AUC 0.76 vs 0.70,P=0.010)。
  • Manhattan风险分组对6个月非复发死亡的预测优于Minnesota风险分类(AUC 0.69 vs 0.64,P=0.009)。
  • MAGIC复合评分每升高一级,第28天治疗反应率显著降低(80% vs 63% vs 30%,P<0.001)。

核心结论

  • MAGIC复合评分比仅基于临床症状的系统更准确地预测治疗反应和长期结局,可能有助于指导临床决策和试验设计。

研究设计与样本

  • 研究将MAGIC联盟中1863例接受GVHD治疗的患者随机分为训练集和验证集。
  • 训练集患者根据临床症状相似性和相近的非复发死亡率分为14组,采用分类回归树(CART)算法创建3个Manhattan风险组。
  • 利用有血清样本的患者,将血清GVHD生物标志物评分与Manhattan风险整合,再次采用CART算法建立3种MAGIC复合评分。

主要发现

  • 在验证集中,Manhattan风险分组对6个月非复发死亡的AUC显著高于Minnesota风险分类(0.69 vs 0.64,P=0.009)。
  • MAGIC复合评分对非复发死亡的预测显著优于Manhattan风险(AUC 0.76 vs 0.70,P=0.010)。
  • MAGIC复合评分每升高一级,第28天治疗反应率显著降低(80% vs 63% vs 30%,P<0.001)。

临床怎么用

  • 作者认为MAGIC复合评分可能有助于指导临床决策和试验设计。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (GVHD) grading systems that use only clinical symptoms at treatment initiation such as the Minnesota risk identify standard and high-risk categories but lack a low-risk category suitable to minimize immunosuppressive strategies. We developed a new grading system that includes a low-risk stratum based on clinical symptoms alone and determined whether the incorporation of biomarkers would improve the model's prognostic accuracy. We randomly divided 1863 patients in the Mount Sinai Acute GVHD International Consortium (MAGIC) who were treated for GVHD into training and validation cohorts. Patients in the training cohort were divided into 14 groups based on similarity of clinical symptoms and similar nonrelapse mortality (NRM); we used a classification and regression tree (CART) algorithm to create three Manhattan risk groups that produced a significantly higher area under the receiver operating characteristic curve (AUC) for 6-month NRM than the Minnesota risk classification (0.69 vs 0.64, P = .009) in the validation cohort. We integrated serum GVHD biomarker scores with Manhattan risk using patients with available serum samples and again used a CART algorithm to establish 3 MAGIC composite scores that significantly improved prediction of NRM compared to Manhattan risk (AUC, 0.76 vs 0.70, P = .010). Each increase in MAGIC composite score also corresponded to a significant decrease in day 28 treatment response (80% vs 63% vs 30%, P < .001). We conclude that the MAGIC composite score more accurately predicts response to therapy and long-term outcomes than systems based on clinical symptoms alone and may help guide clinical decisions and trial design.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Akahoshi Y, Spyrou N, Weber D, et al. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD. Blood. 2024. PMID: 38968143. doi:10.1182/blood.2024025106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。